Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

Wake Forest University at Clemmons, Clemmons

Wake Forest University Health Sciences, Winston-Salem

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables

UM Sylvester Comprehensive Cancer Center at Kendall, Miami

UM Sylvester Comprehensive Cancer Center at Aventura, Aventura

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation

UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach

Moffitt Cancer Center-International Plaza, Tampa

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

University of Alabama at Birmingham Cancer Center, Birmingham

University of Kentucky/Markey Cancer Center, Lexington

Ohio State University Comprehensive Cancer Center, Columbus

Northwestern University, Chicago

University Health Truman Medical Center, Kansas City

The University of Kansas Cancer Center - Olathe, Olathe

University of Kansas Cancer Center, Kansas City

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

University of Kansas Health System Saint Francis Campus, Topeka

Mercy Hospital Pittsburg, Pittsburg

Salina Regional Health Center, Salina

HaysMed, Hays

M D Anderson Cancer Center, Houston

Dana-Farber Cancer Institute, Boston